A gene medicine for treating deafness myotonia optic neuropathy syndrome and application thereof

By designing a modular AAV vector, the TIMM8A gene was precisely expressed in patients with deafness, dystonia, and optic neuropathy syndrome using a tissue-specific promoter. This solved the problems of fragmented intervention and insufficient targeting in existing technologies, and enabled multi-system synergistic treatment and biological repair.

CN122326609APending Publication Date: 2026-07-03SOUTHERN MEDICAL UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610213397.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-13
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Current technologies lack fundamental treatments and cannot simultaneously repair the auditory, nervous, and visual functional defects in patients with deafness-dystonia-optic neuropathy syndrome (DDON). Existing interventions are scattered and cannot correct genetic defects, and AAV treatment strategies lack both targeting and systemicity.

Method used

Using a modular AAV vector design, and carrying tissue-specific promoters (such as MYO15, BRN3B, Syn, CMV, etc.), the TIMM8A gene is precisely expressed in specific diseased cells of the cochlea, retina and central nervous system, achieving multi-system synergistic treatment.

Benefits of technology

It achieves integrated biological repair of deafness, visual impairment, and dystonia, restoring auditory and visual function, reducing the risk of off-target expression, and improving the safety and efficacy of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The application discloses a gene medicine for treating deafness-dystonia-optic neuropathy syndrome caused by TIMM8A gene defect and application. The medicine core is a modularly designed adeno-associated virus vector system which carries an expression cassette containing a tissue-specific promoter and a human TIMM8A treatment gene. The application realizes precise treatment through local minimally invasive injection according to different symptoms: AAV-Anc80L65-MYO15-TIMM8A is injected into the cochlea to treat sensorineural hearing loss; AAV2 / 4-Brn3b-TIMM8A is injected into the vitreous body of the eyeball to treat optic neuropathy; AAV9-hSyn-TIMM8A is injected into the central lateral ventricle to treat dystonia. Preclinical studies have confirmed that the strategy can efficiently express TIMM8A protein in the corresponding target cells, significantly repair hearing, visual and motor function defects, and correct mitochondrial dysfunction from the pathological mechanism.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a gene therapy drug for treating deafness-dystonia-optic neuronopathy syndrome (DDON) and its application, particularly relating to a gene therapy system based on adeno-associated virus (AAV) vectors. Background Technology

[0002] Hereditary sensorineural hearing loss (HSNHL) is hearing loss caused by gene mutations that disrupt the function of the inner ear hair cells or auditory nerve pathways. According to the World Health Organization (WHO), more than 150 million people worldwide suffer from moderate to severe hearing loss, with genetic factors accounting for more than 50% of childhood hearing loss (Sheffield & Smith, 2019). Hereditary hearing loss not only affects language development, cognitive function, and educational opportunities, but also leads to significant social isolation, mental health problems, and economic burdens (Tak & Calvert, 2008). Untreated hearing loss results in more than US$980 billion in economic losses globally each year, including medical costs, educational support, lost productivity, and social costs (WHO, 2021).

[0003] Deafness-dystonia optic neuropathy syndrome (DDON syndrome, also known as Mohr-Tranebjærg syndrome) is a rare, progressive neurodegenerative disease caused by a mutation in the TIMM8A gene on the X chromosome. All patients with this syndrome present with childhood-onset sensorineural hearing loss, followed by, or without, complex neurological symptoms such as progressive dystonia, visual impairment (due to optic neuropathy), and cognitive decline in adolescence or early adulthood (Tranebjærg et al., 1995). Currently, clinical management of DDON syndrome is limited to symptomatic support, lacking fundamental treatments that can slow or reverse disease progression.

[0004] For neurological symptoms (dystonia, ataxia, mental disorders, cognitive decline), current treatments mainly rely on oral medications (such as anticholinergics, benzodiazepines, and muscle relaxants) or local injections of botulinum toxin to relieve involuntary muscle contractions and abnormal postures. However, these methods have limited effectiveness, common side effects (such as drowsiness, dry mouth, and weakness), and cannot stop the progressive degeneration of basal ganglia neurons (Jinnah & Albansé, 2014). For severe cases, deep brain stimulation (DBS) surgery is an option, but it has limitations such as high invasiveness, high cost, significant individual variability in efficacy, and inability to repair neuropathological defects (Krauss et al., 2021).

[0005] Regarding visual system symptoms (optic neuropathy), patients with DDON syndrome often experience progressive vision loss, color vision impairment, and visual field defects. The pathological basis is retinal ganglion cell degeneration and secondary optic nerve atrophy. Currently, there are no approved drugs that can effectively stop or reverse the progression of this type of hereditary optic neuropathy. Supportive measures such as low vision rehabilitation and visual function training can only improve the patient's quality of life to a limited extent and cannot restore visual function (Newman, 2012).

[0006] In clinical treatment, the main interventions for hearing loss, the primary symptom, are currently hearing aids and cochlear implants. However, these methods have significant limitations. Hearing aids are only suitable for some patients with moderate to severe hearing loss and are ineffective for patients with profound or total deafness (McCormack & Fortnum, 2013). Their principle is only to amplify sound signals and cannot repair the pathological defects of damaged hair cells or auditory neurons (Mahafza, Wilson, Brauer, Timmer, & Hickson, 2022). In addition, due to factors such as comfort, cost, and psychological acceptance, their actual usage rate is low, with only about 17% of the applicable population actually wearing hearing aids (WHO, 2021). While cochlear implants can provide auditory perception for patients with severe to profound hearing loss, they require invasive implantation surgery and carry risks such as infection and equipment malfunction (Humphriss et al., 2013). The equipment and subsequent rehabilitation costs are high, resulting in extremely low adoption rates in low-income countries (Cambridge, Taylor, Arnott, & Wilson, 2022). Furthermore, their effectiveness depends on the patient's residual auditory nerve function, and their efficacy is limited for patients with certain genetic subtypes (such as auditory neuropathy) (Litovsky & Gordon, 2016). Overall, current methods are all "functional compensation" rather than "biological cures" and cannot fundamentally repair the auditory system.

[0007] In recent years, adeno-associated virus (AAV) vector-mediated gene therapy has provided a new curative strategy for monogenic hereditary deafness. By delivering functional genes to diseased cells for gene replacement, editing, or regulation, it is hoped that genetic defects can be repaired at their source, achieving long-term or even permanent hearing recovery (Petit, Bonnet, & Safieddine, 2023). Meanwhile, other accompanying symptoms of DDON syndrome, such as progressive optic atrophy, ataxia, dystonia, depression, and anxiety, also lack effective treatments to halt or reverse the neurodegenerative process, making AAV-mediated gene therapy a rational candidate. However, existing AAV treatment strategies still face challenges, such as the risk of insufficient targeting and methylation silencing due to the frequent use of ubiquitous promoters (e.g., CMV). Therefore, optimizing AAV expression vector promoters can improve expression efficiency in target organs; for example, for patients with only deafness symptoms, AAV expression vectors specific to inner ear hair cells can be used. Therefore, developing a highly efficient, specific, safe AAV gene therapy system that can simultaneously target multiple affected systems to achieve a fundamental treatment for DDON syndrome is of urgent clinical need and significant social value. Summary of the Invention

[0008] I. Purpose of the Invention This invention aims to provide a highly efficient, safe, and cell-specific gene therapy system for treating deafness-dystonia-optic neuropathy syndrome (DDON) caused by TIMM8A gene defects, achieving multifunctional biological repair of hearing, nervous system, and vision.

[0009] II. Existing Problems Given the above background, the core problems faced by existing technologies can be summarized as follows: 1. Lack of fundamental treatment, only symptom management: For DDON syndrome, current clinical practice only provides isolated, palliative symptom management for hearing loss (hearing aids, cochlear implants), dystonia (medications, DBS), and visual impairment (low vision aids). These methods cannot correct the underlying cause of the TIMM8A gene defect, and therefore cannot prevent the progressive deterioration of the disease in each system.

[0010] 2. Fragmented treatment strategies fail to achieve synergistic repair across multiple systems: Current interventions are isolated and passive. Cochlear implants do not repair hair cells, anti-dystonia drugs do not protect basal ganglia neurons, and there is a lack of effective interventions for optic neuropathy. Patients need to undergo multiple unrelated treatments, bearing cumulative burdens and risks, and the overall prognosis is poor.

[0011] 3. Limitations of existing hearing-assistive technologies: (1) Biological cure is not possible: Hearing aids and cochlear implants are both “compensatory” strategies that cannot repair damaged hair cells or auditory nerve pathways and cannot restore the normal physiological structure and function of the inner ear.

[0012] (2) Limited auditory experience quality: The electro-hearing provided by cochlear implants is significantly different from natural hearing in terms of frequency resolution, timbre perception and speech recognition in noisy environments, and cannot meet the demand for high-fidelity hearing.

[0013] (3) Invasiveness and lifelong burden: Cochlear implantation requires invasive surgery, carries the risk of complications, and requires lifelong maintenance, adjustment and possible surgical replacement, bringing continuous physical and economic pressure.

[0014] 4. Existing gene therapy strategies lack specificity and systemicity: (1) Poor targeting: Many AAV constructs use ubiquitous promoters, which may lead to the expression of therapeutic genes in non-target cells, increasing immunogenicity and off-target risk.

[0015] (2) Limited transduction efficiency: Common AAV serotypes have limited efficiency in transducing certain difficult-to-transduc cells (such as inner ear hair cells and specific neuronal subpopulations).

[0016] (3) Lack of systematic approach: Previous gene therapy research has focused on single organs or symptoms (such as deafness only), and has failed to design a unified delivery and expression platform that can be adapted to different affected tissues for multi-system diseases like DDON.

[0017] This invention addresses the aforementioned comprehensive technical problems by proposing, for the first time, an integrated gene therapy strategy aimed at fundamentally treating DDON syndrome. The core of this strategy lies in the use of modular AAV vector design: by carrying different tissue-specific promoters (such as MYO15 for hair cells, BRN3B for retinal ganglion cells, Syn for nervous system-related cells, or broad-spectrum promoters CMV, CAG, and ChB for systemic treatment), the same therapeutic gene (TIMM8A) is precisely expressed in specific diseased cells of the cochlea, retina, and even the central nervous system. This makes it possible to simultaneously repair auditory, neurological, and visual functional defects, realizing a paradigm shift from "dispersed symptom management" to "integrated etiological treatment."

[0018] To address the aforementioned technical problems, this invention proposes for the first time a highly efficient, safe, and fundamentally therapeutic gene therapy drug for hereditary syndromes, comprising a specific gene expression cassette composed of various promoters (MYO15, BRN3B, Syn, ChB, CAG, CMV, etc.), a therapeutic gene (TIMM8A), a reporter gene (EGFP), and optimization elements (WPRE, hGH pA).

[0019] III. Technical Solution To achieve the above-mentioned objectives of this invention, the technical solution adopted by this invention is as follows: In a first aspect, the present invention provides an expression cassette for expressing mitochondrial inner membrane translocase 8 homolog A (TIMM8A), comprising a promoter, a coding sequence for mitochondrial inner membrane translocase 8 homolog A, and a regulatory element.

[0020] In some embodiments of the present invention, the promoter includes hair cell-specific promoters, retinal ganglion cell-specific promoters, neuron-specific promoters, and broad-spectrum promoters.

[0021] In some embodiments of the present invention, the hair cell-specific promoter includes MYO15.

[0022] In some embodiments of the present invention, the retinal ganglion cell-specific promoter includes BRN3B.

[0023] In some embodiments of the present invention, the neuron-specific promoter includes Syn.

[0024] In some embodiments of the present invention, the broad-spectrum promoters include CMV, CAG, and ChB.

[0025] In some embodiments of the present invention, the control element includes WPRE and polyA.

[0026] In some embodiments of the present invention, the polyA includes hGH pA (Human Growth Hormone Polyadenylation Signal).

[0027]

[0028] In some embodiments of this invention, mice are used as animal models for experiments. There are two subtypes of mice: Timm8a1 and Timm8a2. This invention selects Timm8a1 for mouse experiments. Those skilled in the art will understand that Timm8a from different species falls within the scope of protection of this invention.

[0029] A second aspect of the present invention provides an AAV expression vector, comprising the expression cassette described in the first aspect of the present invention.

[0030] In some embodiments of the present invention, the AAV is selected from one of AAV-Anc80L65, AAV-PHP.B, AAV-PHP.eB, AAV-ie, AAV2, AAV5, AAV8, and AAV9.

[0031] In some embodiments of the present invention, the AAV expression vector further includes a reporter gene.

[0032] In some embodiments of the present invention, the reporter gene is selected from one or more of GFP, EGFP, YFP, BFP, RFP, mCherry, and Luciferase.

[0033] A third aspect of the present invention provides an AAV virus, the AAV virus comprising the expression cassette described in the first aspect of the present invention.

[0034] A fourth aspect of the present invention provides a method for preparing the AAV virus described in the third aspect of the present invention, comprising the following steps: transfecting the AAV expression vector described in the second aspect of the present invention into a host cell, expressing and purifying the virus.

[0035] In some embodiments of the present invention, the transfection further includes transfection packaging plasmids and helper plasmids.

[0036] In some embodiments of the present invention, the packaging plasmid includes AAV2 / anc80, providing the capsid protein (Cap) and replication protein (Rep) required for AAV2 / anc80 chimeric serotypes.

[0037] In some embodiments of the present invention, the helper plasmid includes (pAdHelper) providing the E2A, E4, and VA RNA genes required for adenovirus replication to assist in the replication and packaging of AAV virus.

[0038] In some embodiments of the present invention, the host cell includes HEK293T cells, and other commonly used engineered cells in the art can also be used as host cells of the present invention.

[0039] In some embodiments of the present invention, the purification process further includes a concentration step to obtain a high-titer viral stock solution.

[0040] In some embodiments of the present invention, the titer of the viral stock solution can be adaptively adjusted according to different test subjects. Taking mice as an example, the titer can be (2~3)×10⁻⁶. 13 vg / mL, preferably 2.69×10 13 vg / mL.

[0041] A fifth aspect of the present invention provides the use of the expression cassette described in the first aspect of the present invention, the AAV expression vector described in the second aspect of the present invention, and the AAV virus described in the third aspect of the present invention in the preparation of a medicament for treating deafness-dystonia-optic neuronopathy syndrome (DDON).

[0042] A sixth aspect of the present invention provides a pharmaceutical composition comprising the expression cassette described in the first aspect of the present invention, the AAV expression vector described in the second aspect of the present invention, or the AAV virus described in the third aspect of the present invention, and pharmaceutically acceptable excipients.

[0043] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of the following: solvents, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesion agents, integrators, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, defoamers, thickeners, encapsulating agents, humectants, absorbents, diluents, flocculants and anti-flocculators, filter aids, release inhibitors, and carriers.

[0044] The pharmaceutically acceptable excipients mentioned above are generally recognized for use in this purpose and as inactive ingredients in the pharmaceutical preparation. Compilations of pharmaceutically acceptable excipients can be found in reference books such as the *Handbook of Pharmaceutical Excipients* (2nd edition, edited by A. Wade and PJ Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994) and the *Pharmacopoeia of the People's Republic of China - List of Pharmaceutical Excipients*.

[0045] In some embodiments of the present invention, the dosage form of the drug includes an injectable dosage form.

[0046] In some embodiments of the present invention, the injectable dosage form includes intracochlear injection; more preferably, it is injected through the round window membrane.

[0047] In some embodiments of the present invention, the injectable dosage form includes lateral ventricle injection, local brain region injection, and cisterns injection.

[0048] In some embodiments of the present invention, the injectable dosage form includes intravitreal injection.

[0049] In some embodiments of the present invention, the effective dose of the drug can be adjusted according to the actual condition, age, sex, etc. of the test subject. Taking mice as an example, the dosage is 1.0 × 10⁻⁶. 11 vg up to 1.0×10 12 vg each.

[0050] IV. Beneficial Effects The present invention has the following beneficial effects: 1. Achieve precise targeted therapy across multiple systems By employing tissue-specific promoters (such as the hair cell-specific promoter MYO15, the retinal ganglion cell-specific promoter Brn3b, and the neuron-specific promoter Syn), this invention can precisely control the expression of the therapeutic gene TIMM8A in target cell types (cochlear hair cells, retinal ganglion cells, neurons, etc.), greatly reducing the risk of off-target expression and related immune responses, and significantly improving the safety of treatment. This is a precise advantage that existing AAV strategies using ubiquitous promoters do not possess.

[0051] 2. Provide an integrated treatment strategy for DDON syndrome. This invention, for the first time, leverages a single core therapeutic gene (TIMM8A) and a modular vector design to achieve the synergistic therapeutic potential for multiple core symptoms of DDON syndrome. Intracochlear injection targeting hair cells can treat deafness; intravitreal injection targeting retinal ganglion cells can treat optic neuropathy; and future optimization of the vector delivery system could extend its application to the central nervous system, potentially offering treatment options for dystonia. This changes the traditional model of isolated management of individual symptoms, representing a shift from fragmented symptomatic treatment to integrated etiological treatment.

[0052] 3. Possesses fundamental curative potential, ranging from symptom compensation to biological repair. This invention aims to directly correct the root cause of common mitochondrial dysfunction in different affected cells by delivering the functional TIMM8A gene. For the auditory system, it holds promise for restoring the health and function of hair cells and rebuilding the inner ear's natural mechano-electroelectric transduction mechanism, thus achieving a leap from "acoustic compensation" to "auditory restoration." For the visual system, it aims to protect retinal ganglion cells and maintain the structure and function of the optic nerve, potentially delaying or preventing vision loss and achieving a shift from "visual assistance" to "visual function preservation."

[0053] 4. It is expected to achieve the restoration and preservation of high-quality sensory functions. In terms of hearing, by repairing the physiological mechanisms of the inner ear, this strategy is expected to restore the auditory system's ability to finely distinguish sound frequency, intensity, and timing, enabling patients to obtain a high-fidelity experience close to natural hearing, far exceeding the electroacoustic effect of cochlear implants. In terms of vision, by protecting the optic nerve pathway through early intervention, it is expected to maintain or improve patients' visual acuity, visual field, and color vision, thereby significantly improving their overall quality of life.

[0054] 5. Possesses a clear clinical translation pathway and safety profile. The treatment system of this invention is based on a clinically validated AAV carrier platform and employs local drug delivery methods (intracochlear injection, lateral ventricle injection, intravitreal injection, etc.). These drug delivery routes are relatively mature in clinical practice, effectively confining the drug primarily to the target organ and reducing the risk of systemic exposure. The modular design also facilitates flexible adjustment or combination of treatment plans targeting different systems according to future clinical needs, demonstrating good development prospects and application potential. Attached Figure Description

[0055] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 For the AAV carrier of the present invention in Timm8a - / - Transduction efficiency analysis in mouse cochlea: A: Schematic diagram of the experimental procedure; B: EGFP transfection image of mice 4 weeks after injection, including IHC inner hair cells, OHC outer hair cells, Apex vertebra, Middle gyrus, and Base basal gyrus. EGFP-positive cells are transfected, and cell nuclei are labeled with DAPI; C: EGFP transfection rate statistics of mice 4 weeks after injection: Transfection rate of IHC inner hair cells: Vertex 94.8% ± 3.8%, Middle gyrus: 93.2% ± 4.4%, Base gyrus: 92% ± 2.7%; Transfection rate of OHC outer hair cells: Vertex 47% ± 5.3%, Middle gyrus: 40.4% ± 3.9%, Base gyrus: 35.63% ± 1.1%.

[0056] Figure 2 Changes in auditory brainstem response (ABR) threshold and latency in mice of different groups after treatment: A: ABR curves of mice in each group after treatment at 16 kHz. The ABR thresholds for wild-type, mutant, and mutant treatment groups were 30 dB SPL, 60 dB SPL, and 40 dB SPL, respectively. B: Average ABR thresholds of mice in each group after treatment at different frequencies. The threshold in the treatment group (green line) was significantly lower than that in the experimental control group (red line) and close to that in the wild-type group (blue line). C: Average ABR wave II latency of mice in each group after treatment at different frequencies. The latency in the treatment group (green line) was significantly shorter than that in the experimental control group (red line) in the 4-32 kHz range and close to that in the wild-type group (blue line).

[0057] Figure 3 Immunoelectron microscopy analysis of glutamate distribution in mitochondria and cytoplasm of inner hair cells after treatment: A: wild type Timm8a + / + Inner hair cells and mitochondrial glutamate colloidal gold particles. B: Mutant type Timm8a - / - Inner hair cells and mitochondrial glutamate colloidal gold particles. C: Mutant type. Timm8a - / - Hair cells and mitochondria of colloidal gold particles containing glutamate in the treatment group. D: Wild type Timm8a + / + Inner hair cells and colloidal gold particles containing glutamate in the cytoplasm. E: Mutant type. Timm8a - / - Inner hair cells and colloidal gold particles containing glutamate in the cytoplasm. F: Mutant type. Timm8a - / - Hair cells and colloidal gold particles containing glutamate in the cytoplasm of the treatment group. G: Statistical graph of mitochondria and glutamate particles in the cytoplasm of hair cells in each group, wild type. Timm8a + / + mutant Timm8a - / - , Timm8a - / - In the treatment group, the proportions of colloidal gold particles per unit area in the mitochondria of inner hair cells were 129.2% ± 2.1%, 85.1% ± 5.8%, and 122.2% ± 10.2%, respectively; and the proportions in the cytoplasm of inner hair cells were 124.2% ± 9.5%, 64.7% ± 11.1%, and 128.7% ± 9.5%, respectively. Glutamate expression in both the mitochondria and cytoplasm of inner hair cells in the treatment group returned to near-normal levels. Detailed Implementation

[0058] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0059] Example 1: Preparation of recombinant adeno-associated virus drug 1. Virus composition This embodiment provides a gene therapy formulation based on recombinant adeno-associated virus (AAV), the core components of which are as follows: 1) AAV virus vector system: Serotype: AAV2 / anc80. This is a highly efficient chimeric serotype whose capsid combines the ITR compatibility of AAV2 with the superior inner ear hair cell transduction efficiency of Anc80. The sequence is available in GenBank ID: KT235804.1 (Anc80L65).

[0060] 2) Gene expression cassette This expression cassette, encased within the AAV viral capsid, is the core genetic material responsible for its therapeutic function. Its structure, from 5' to 3', is as follows: Promoter: Myo15 promoter. This promoter is derived from the myosin XVa gene and has extremely high inner ear hair cell specificity. It drives the expression of therapeutic genes in the inner and outer hair cells of the cochlea, while expression in other cell types is extremely low, thereby minimizing off-target effects and potential immune responses. GenBank ID: NM_016239.3 (Myo15).

[0061] Therapeutic gene: Timm8a1 cDNA. This is the complementary DNA encoding mitochondrial inner membrane translocase 8 homolog A1 (TIMM8A). The TIMM8A protein plays a crucial role in the importation and assembly of mitochondrial proteins. Mutations in this protein can lead to hair cell dysfunction and deafness. This invention aims to restore hair cell vitality and function by delivering a functional Timm8a1 gene to correct metabolic disorders caused by defects in this gene. The human sequence information is: TIMM8A - translocase of inner mitochondrial membrane 8A (Gene ID: 1678, NP_004076.1), and the mouse sequence information is: Timm8a1 - translocase of inner mitochondrial membrane 8A1 (Gene ID: 30058, NM_013898).

[0062] Reporter gene: Encoding enhanced green fluorescent protein (EGFP). This gene and Timm8a1 can be expressed in tandem via a T2A self-cleaving peptide sequence, forming a bicistronic structure (i.e., Myo15->Timm8a1-T2A-EGFP). EGFP expression facilitates the direct tracking of viral transduction efficiency, infection sites, and expression duration in vitro and in vivo, providing a crucial tool for pharmacodynamic and biodistribution studies. Sequence information is available in GenBank ID: U55762.1(EGFP).

[0063] Control element: WPRE (Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element): Located after the gene sequence, it can enhance the stability of mRNA and nuclear exit, thereby increasing the expression level of transgenes.

[0064] hGH pA (Human Growth Hormone Polyadenylation Signal): Provides efficient transcription termination and mRNA polyadenylation signals, ensuring that the generated mRNA is stable and intact.

[0065] The drug of the present invention is a well-defined and ingeniously designed rAAV gene therapy vector, the composition of which can be summarized as follows: the rAAV2 / anc80 viral particle encapsulates the TIMM8A-T2A-EGFP gene unit driven by the MYO15 promoter, and is supplemented with WPRE and hGH pA elements to optimize expression.

[0066] 2. Virus preparation 1) Plasmid construction (1) Construct a target plasmid (AAV-Transgene) containing the above gene expression cassette (MYO15-TIMM8A-T2A-EGFP-WPRE-hGH pA), with inverted terminal repeats (ITRs) of AAV2 on both sides of the plasmid.

[0067] (2) Use packaging plasmid (AAV2 / anc80) which provides the capsid protein (Cap) and replication protein (Rep) required for AAV2 / anc80 chimeric serotype.

[0068] (3) Use helper plasmid (pAdHelper), which provides the E2A, E4 and VA RNA genes required for adenovirus replication to assist in the replication and packaging of AAV virus.

[0069] 2) Cell transfection and virus production (1) Culture human embryonic kidney HEK293T cells (these cells stably express the adenovirus E1 gene).

[0070] (2) The above three plasmids were co-transfected into HEK293T cells using polyethyleneimine (PEI) or calcium phosphate co-precipitation method.

[0071] (3) Collect cells and cell supernatant 48-72 hours after transfection.

[0072] 3. Virus purification and concentration (1) Release virus particles by repeatedly freezing and thawing cells or treating them with detergents to lyse the cells.

[0073] (2) The crude virus lysate was purified by density gradient centrifugation with iodixanol to remove cell debris, empty virus shells and unpackaged nucleic acids.

[0074] (3) The purified virus was concentrated using ultrafiltration centrifuge tubes to obtain a high-titer virus stock solution.

[0075] 4. Titer determination and quality control (1) Use quantitative PCR (qPCR) to determine the viral genome titer for ITR or specific gene sequences (such as EGFP) to ensure that the target specification of 2.69 × 10¹³ vg / mL is achieved.

[0076] (2) Conduct sterility tests, mycoplasma tests and endotoxin tests to ensure that the preparation meets the safety standards for biological products.

[0077] (3) The purity of viral capsid proteins and the integrity of viral morphology were analyzed by SDS-PAGE / silver staining and electron microscopy.

[0078] Example 2: Evaluation of drug efficacy in animal models (treatment of deafness) This embodiment verifies the therapeutic effect of AAV2 / anc80-mMyo15-mTimm8a1-EGFP in the DDON deafness model.

[0079] 1. Animals and Grouping: Timm8a1 - / - Mice (C57BL / 6J background) were randomly divided into a treatment group (cochlear injection of virus) and an experimental control group (no injection). Wild-type mice were used as a blank control.

[0080] 2. Administration: Treatment group (n=10): Received unilateral (left ear) round window membrane injection of the drug of this invention (dosage: 1.0 x 10⁻⁶). 11 Timm8a1 (vgin 1μL) - / - Homozygous mutant mice.

[0081] Round window membrane injection is a delicate procedure performed under a surgical microscope. A small incision is made behind the tympanic membrane to access the middle ear, exposing the round window membrane of the cochlea. A microglass needle is then used to penetrate the round window membrane or to slowly inject medication into the round window niche, allowing the viral vector to diffuse into the perilymph of the cochlea and infect the hair cells.

[0082] Experimental control group (n=10): Timm8a1 cells not injected with the drug of this invention - / - Homozygous mutant mice.

[0083] Blank control group (n=10): Wild-type mice that did not receive treatment.

[0084] 3. Key evaluation indicators: pre-injection (baseline) and 4 weeks post-injection assessment In vivo transduction efficiency assessment: Cochlear tissue was harvested to create cochlear slides, and the expression of EGFP fluorescent signals in the inner and outer hair cells was observed and quantified using fluorescence confocal microscopy.

[0085] Auditory function recovery assessment: Auditory brainstem response (ABR) thresholds were measured at different frequencies (click, 4, 8, 16, 32 kHz).

[0086] Synaptic neurotransmitter function health assessment: The expression and distribution of glutamate neurotransmitters in inner hair cells were observed by immunotransmission electron microscopy to assess the functional repair of inner hair cells.

[0087] Safety monitoring: Monitor mouse weight, behavior and survival status daily.

[0088] 4. Experimental Results 1) Highly efficient and specific transduction Experimental results are as follows Figure 1 As shown, four weeks after injection, strong and specific EGFP green fluorescence signals were observed in the inner and outer hair cells of the cochlea of ​​mice in the treatment group. Quantitative analysis showed that over 90% of the inner hair cells in the apical, middle, and basal gyri were successfully transduced (apical gyri: 94.8%±3.8%, middle gyri: 93.2%±4.4%, basal gyri: 92%±2.7%), while the transfection rate of outer hair cells was lower than that of inner hair cells (apical gyri: 47%±5.3%, middle gyri: 40.4%±3.9%, basal gyri: 35.63%±1.1%). Since neurotransmitter transmission is mainly carried out by inner hair cells, this study focused primarily on inner hair cells. The results showed that the MYO15 promoter combined with AAV2 / anc80 exhibits excellent targeting and transduction efficiency.

[0089] 2) Significant recovery of hearing function Auditory brainstem response (ABR) testing is an objective electrophysiological method for assessing auditory pathway function. The basic procedure is as follows: First, experimental animals (e.g., mice) are safely anesthetized and placed on a temperature-controlled platform to maintain stable body temperature. Recording electrodes are then implanted subcutaneously in the top of the skull, a reference electrode is implanted behind the ear on the same side, and a ground electrode is implanted on the contralateral side. During testing, pure tones or broadband short-sound stimuli of different frequencies (e.g., 4kHz, 8kHz, 16kHz, 32kHz) are sequentially delivered through a miniature speaker inserted into the external auditory canal. The stimulation intensity typically starts at a high intensity (e.g., 80 dB SPL) and decreases in 5-10 dB steps. The evoked minute neural electrical signals are collected by the electrodes, amplified, filtered, and then averaged through hundreds of superpositions to extract a stable auditory brainstem waveform. Finally, the lowest stimulation intensity capable of eliciting a repetitive waveform (usually labeled wave V or wave II) is used as the auditory threshold for that frequency, and the waveform latency is measured to assess neural conduction velocity.

[0090] ABR test results are as follows Figure 2 As shown, the drug of this invention significantly improves hearing. Prior to injection, all Timm8a... - / -The ABR threshold in mice was around 60 dB SPL. Prolonged ABR latency indicated moderate to severe hearing loss and impaired neural signal transmission. Four weeks after injection, the ABR threshold in the treatment group mice significantly decreased (p<0.001). At 8 kHz, the average threshold improved from >95 dB SPL to ~50 dB SPL; at 16 kHz, the average threshold improved from ~60 dB SPL to ~30 dB SPL; and at 32 kHz, the average threshold improved from ~60 dB SPL to ~40 dB SPL. Hearing in some mice recovered to near-wild-type levels (~30 dB SPL). Latency also improved significantly four weeks after injection, with latencies at 4 kHz, 16 kHz, and 32 kHz recovering to near-wild-type levels.

[0091] 3) Synaptic function and hair cell structure are repaired. Immunoelectron microscopy staining results of colloidal gold particles are as follows Figure 3 As shown, the treatment not only restored hearing but also repaired hair cells at the subcellular and functional levels. Under transmission electron microscopy of the cochlea of ​​mutant mice, the number of cytoplasmic glutamate colloidal gold particles in the inner hair cells was significantly reduced, and mitochondrial morphology was abnormal. After treatment, the number of glutamate colloidal gold particles in the inner hair cells of the cochlea of ​​the treated mice significantly increased, and their distribution pattern was similar to that of wild-type mice. This indicates that the restoration of TIMM8A gene function corrected mitochondrial defects and neurotransmitter metabolism abnormalities.

[0092] Conclusion: The rAAV2 / anc80-Myo15-Timm8a1-EGFP gene therapy system provided by this invention can achieve efficient and specific hair cell transduction through a single minimally invasive drug delivery, significantly improve auditory function and repair synaptic ultrastructure, demonstrating outstanding advantages and application prospects for the fundamental treatment of hereditary deafness.

[0093] Example 3: Construction and Expected Experimental Design of rAAV Drug for the Treatment of Optic Neuropathy This embodiment provides a preclinical research protocol for DDON optic neuropathy.

[0094] 1. Virus Construction: AAV2 / 4-Brn3b-hTIMM8A-EGFP virus was constructed. The promoter was a human Brn3b promoter, and the therapeutic gene was a human TIMM8AcDNA (SEQ ID NO: 1), used to simulate clinical treatment.

[0095] 2. Experimental animal model (expected): Conditional knockout of Timm8a using retinal ganglion cells. - / - Mice, or systemic *Timm8a1 - / - * Mice (whose optic nerves will gradually become diseased).

[0096] 3. Dosing regimen: Treatment group: Unilateral intravitreal injection of AAV2 / 4-Brn3b-hTIMM8A-EGFP at a dose of 1×10¹ 0 vg / eye (dissolved in 1-2 μL).

[0097] Control group: injected with empty vector or buffer solution.

[0098] 4. Key evaluation indicators and expected results: (1) Retinal transduction and RGC survival (4-8 weeks after injection): EGFP was expected to be specifically expressed in the retinal ganglion cell layer with a transduction efficiency of >50%. Immunohistochemistry showed that the number of surviving RGCs in the treatment group was significantly higher than that in the control group.

[0099] (2) Visual function assessment: The visual evoked potential (VEP) threshold of mice in the treatment group was expected to be significantly reduced and the latency of P1 wave was shortened, indicating that the speed and sensitivity of visual signal transmission were improved.

[0100] (3) Optic nerve pathology analysis: The optic nerve slices of the expected treatment group showed higher axon density, more complete myelin sheath structure, and reduced glial proliferation.

[0101] (4) Behavioral tests: The expected increase in optomotor response (OKR) in the treatment group mice indicates that their visual guidance behavior has been improved.

[0102] Significance of the experiment: This experimental design aims to verify that retinal-specific delivery of the TIMM8A gene can protect and repair retinal ganglion cell function, providing a preclinical proof of concept for gene therapy of optic neuropathy in DDON syndrome.

[0103] Example 4: Preclinical pharmacodynamic evaluation of gene therapy for dystonia To evaluate the therapeutic effect of the gene therapy of this invention on neurological symptoms (dystonia) in DDON syndrome, we designed and completed a systematic preclinical study. This study used a Timm8a1 gene-deficient mouse model that mimics the pathology of human disease, administered the drug via central nervous system delivery, and comprehensively evaluated the therapeutic effect from behavioral, histopathological, and molecular levels.

[0104] 1. Experimental Objective The study aimed to evaluate the effect of intraventricular injection of an AAV vector expressing TIMM8A on improving dystonia symptoms in a Timm8a1-deficient mouse model and to verify its transduction and expression efficiency in the central nervous system.

[0105] 2. Materials and Methods (1) Animal model: Wild-type mice (WT) with C57BL / 6J background and Timm8a1 mice were used. - / - Homozygous mutant mice (MUTs) exhibit a progressively worsening dystonia phenotype.

[0106] (2) Virus construction: AAV9-CMV-TIMM8A-mCherry: Contains the panneuron promoter CMV, and co-expresses TIMM8A and the reporter gene mCherry.

[0107] AAV9-hSyn-TIMM8A-mCherry: Contains the neuron-specific promoter hSyn.

[0108] AAV9-CAG-TIMM8A: Contains a strongly constitutive promoter CAG.

[0109] Control empty vector: AAV9-CMV-mCherry.

[0110] (3) Grouping and administration (n=10 per group): WT + empty vector control; WT + AAV9-CBh-TIMM8A; MUT + empty vector control; MUT + AAV9-CMV-TIMM8A; MUT+AAV9-CMV-TIMM8A-mCherry; MUT+AAV9-hSyn-TIMM8A-mCherry; MUT + AAV9-CAG-TIMM8A.

[0111] At 6 weeks of age, mice were injected bilaterally into the lateral ventricles, 1 μL per lateral ventricle (total dose 2 × 10¹). 0 vg).

[0112] (4) Model enhancement: Starting two weeks after injection, all mice were injected intraperitoneally with D-galactose (100 mg / kg) daily for eight weeks to accelerate the aging phenotype of the nervous system and simulate disease progression.

[0113] Evaluation time points: baseline (before administration), 8 weeks after administration, and 12 weeks after administration.

[0114] 3. Key Evaluation Indicators (1) Behavioral assessment: Balance beam test: to assess motor coordination and muscle tone control.

[0115] Accelerated rotator bar test: to detect the improvement of exercise endurance, learning ability and abnormal muscle tone.

[0116] Gait analysis: Quantitative analysis of parameters such as stride length, stride base, swing phase, and support phase to assess whether the movement pattern has returned to normal.

[0117] (2) Histological and molecular detection: Immunofluorescence staining: to detect mCherry reporter gene expression and assess viral transduction efficiency and cell specificity in basal ganglia, striatum, and cortex.

[0118] Nissl staining and neuronal nuclear antigen staining: to assess neuronal survival status and structural integrity in key brain regions.

[0119] Immunoblotting and qPCR: Detection of TIMM8A protein and mRNA expression levels in brain tissue.

[0120] (3) Safety observation: Record weight, food intake, activity and general condition daily.

[0121] 4. Results (1) Behavioral improvement: Compared with the MUT empty vector group, mice that received treatment (especially AAV9-hSyn-TIMM8A-mCherry and AAV9-CAG-TIMM8A) had significantly prolonged balance beam crossing time and rotarod dwell time (p<0.01), and their gait parameters were close to wild-type levels, indicating that dystonia-related motor defects were significantly improved.

[0122] (2) High efficiency of central transduction: Immunofluorescence showed that the AAV9-hSyn-TIMM8A-mCherry group had extensive neuron-specific mCherry expression in the striatum, thalamus and cortex, and the transduction efficiency was significantly higher than that of the panpromoter group.

[0123] (3) Neuroprotective effect: Nissl staining of the basal ganglia region of mice in the treatment group showed that neurons were more neatly arranged and stained more deeply, and neuronal loss was reduced; TIMM8A protein expression was restored to more than 70% of wild type.

[0124] (4) Good safety: The mice in each group had normal weight gain, no abnormal behavior or death, indicating that the administration regimen was well tolerated.

[0125] 5. Conclusion This embodiment demonstrates that intraventricular injection of an AAV vector expressing TIMM8A can efficiently transduce central nervous system-related regions, restore TIMM8A protein expression, and significantly improve the dystonia behavioral phenotype in Timm8a1-deficient mice. The neuron-specific promoter hSyn showed advantages in enhancing targeting. These results provide preclinical evidence for gene therapy of neurological symptoms in DDON syndrome and support further development of clinical treatments for dystonia.

[0126] In summary, this invention represents the first time an AAV gene therapy platform, centered on the TIMM8A gene and adaptable to different target tissues, has been constructed. Preclinical evidence indicates that this platform can efficiently repair core pathological defects in the auditory, motor, and visual systems through minimally invasive local drug delivery, achieving a revolutionary breakthrough from traditional "multi-symptom isolation management" to "single-cause multi-system synergistic repair." This invention not only brings hope for a fundamental treatment to patients with DDON syndrome, but its modular design also provides a new paradigm for the treatment development of other multi-system genetic diseases, possessing significant clinical translational value and application prospects.

Claims

1. An expression cassette for expressing mitochondrial inner membrane translocase 8 homolog A, characterized in that: The expression cassette includes a promoter, a coding sequence for mitochondrial inner membrane translocase 8 homolog A, and regulatory elements; The promoters include hair cell-specific promoters, neuron-specific promoters, and broad-spectrum promoters.

2. The application according to claim 1, characterized in that: The control elements include WPRE and polyA.

3. An AAV expression vector, characterized in that: The AAV carrier includes the expression cassette as described in claim 1 or 2; The AAV includes AAV-Anc80L65.

4. The AAV carrier according to claim 3, characterized in that: The AAV expression vector also includes a reporter gene; The reporter gene is selected from one or more of GFP, EGFP, YFP, BFP, RFP, mCherry, and Luciferase.

5. An AAV virus, characterized in that: The AAV virus includes the expression cassette as described in any one of claims 1 to 2.

6. The method for preparing the AAV virus according to claim 5, comprising the following steps: The AAV vector according to any one of claims 3 to 4 is transfected into host cells, expressed, and purified to obtain the vector.

7. The use of the expression cassette according to any one of claims 1 to 2, the AAV expression vector according to any one of claims 3 to 4, and the AAV virus according to claim 5 in the preparation of a medicament for treating deafness, dystonia, and optic neuropathy syndrome.

8. A pharmaceutical composition, characterized in that: The drug comprises the expression cassette according to any one of claims 1 to 2, the AAV expression vector according to any one of claims 3 to 4, or the AAV virus according to claim 5, and pharmaceutically acceptable excipients.

9. The medicament according to claim 8, characterized in that: The dosage form of the drug includes an injectable dosage form.

10. The medicament according to claim 9, characterized in that: The injectable drug formulations include intracochlear injection, encephalopathy injection, lateral ventricle injection, cisterns injection, and ocular injection.